中国药房2011，Vol.22Issue(6)：529-531,3.
贝伐单抗联合培美曲塞加卡铂二线治疗晚期非小细胞肺癌的临床观察
Clinical Observation of Second Line Treatment of Bevacizumab Combined with Pemetrexed and Carboplatin for Advanced Non-Small Cell Lung Cancer
摘要
Abstract
OBJECTIVE: To observe the clinical efficacy and adverse drug reaction of second line treatment of bevacizumab combined with pemetrexed and carboplatin for advanced non-small cell lung cancer(NSCLC).METHODS: 30 advanced NSCLC patients were divided into experimental group (10 cases, bevacizumab 15 mg·kg-1 +pemetrexed 500 mg·m-2+carboplatin AUC6)and control group (20 cases, pemetrexed 500 mg·m-2+ carboplatin AUC6) by the method of random number table with 21 days as one cycle.Therapeutic efficacy and adverse drug reaction of two cycles were evaluated.RESULTS: The disease control rates (DCR) of the experimental group and control group were 80.0％ and 40.0％ (P＜0.05).Median progression-free survival (MPFS)of the two groups are 4.7 months and 3.2 months (P＜0.05), and the response rates of the two groups were 20.0％ and 5.0％ (P＞0.05).The median survival time (MST) of the two groups were 9.2 months and 7.9 months (P＞0.05).There was no significant difference in adverse drug reaction between two groups (P＞0.05).CONCLUSION: Second line treatment of bevacizumab combined with pemetrexed and carboplatin for advanced non-small cell lung cancer is better than pemetrexed combined with carboplatin in respect of DCR and MPFS with no difference in adverse drug reaction and can be tolerant.关键词
非小细胞肺癌/贝伐单抗/培美曲塞/卡铂/化疗分类
医药卫生引用本文复制引用
周立霞,哈敏文..贝伐单抗联合培美曲塞加卡铂二线治疗晚期非小细胞肺癌的临床观察[J].中国药房,2011,22(6):529-531,3.
